Japan: These 55 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Japan
Generic Entry Dates in Other Countries
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Summary: Japan: These 55 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
Tradename | Ingredient | Estimated Entry Opportunity Date |
---|---|---|
CREON | pancrelipase (amylase;lipase;protease) | 2025-08-15 |
ERIVEDGE | vismodegib | 2024-09-02 |
ESBRIET | pirfenidone | 2025-09-22 |
OLYSIO | simeprevir sodium | 2025-07-29 |
>Tradename | >Ingredient | >Estimated Entry Opportunity Date |
Details: Japan: These 55 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2025
Generic Entry Controlled by: Japan Patent 2,009,504,709
CREON is a drug marketed by There has been litigation on patents covering CREON
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2025
Generic Entry Controlled by: Japan Patent 2,009,504,710
CREON is a drug marketed by There has been litigation on patents covering CREON
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2025
Generic Entry Controlled by: Japan Patent 5,284,092
CREON is a drug marketed by There has been litigation on patents covering CREON
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2025
Generic Entry Controlled by: Japan Patent 5,452,918
CREON is a drug marketed by There has been litigation on patents covering CREON
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ERIVEDGE (vismodegib) generic drug versions launch?
Generic name: vismodegib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2024
Generic Entry Controlled by: Japan Patent 2,008,511,675
ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.
This drug has fifty-four patent family members in twenty-four countries.
See drug price trends for ERIVEDGE.
The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.
When can ERIVEDGE (vismodegib) generic drug versions launch?
Generic name: vismodegib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2024
Generic Entry Controlled by: Japan Patent 2,012,184,255
ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.
This drug has fifty-four patent family members in twenty-four countries.
See drug price trends for ERIVEDGE.
The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.
When can ERIVEDGE (vismodegib) generic drug versions launch?
Generic name: vismodegib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2024
Generic Entry Controlled by: Japan Patent 2,014,148,537
ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.
This drug has fifty-four patent family members in twenty-four countries.
See drug price trends for ERIVEDGE.
The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.
When can ERIVEDGE (vismodegib) generic drug versions launch?
Generic name: vismodegib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 02, 2024
Generic Entry Controlled by: Japan Patent 5,143,558
ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.
This drug has fifty-four patent family members in twenty-four countries.
See drug price trends for ERIVEDGE.
The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2025
Generic Entry Controlled by: Japan Patent 2,009,509,962
ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-two patent family members in forty-five countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2025
Generic Entry Controlled by: Japan Patent 2,012,224,641
ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-two patent family members in forty-five countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2025
Generic Entry Controlled by: Japan Patent 2,014,169,341
ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-two patent family members in forty-five countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2025
Generic Entry Controlled by: Japan Patent 5,715,101
ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-two patent family members in forty-five countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2025
Generic Entry Controlled by: Japan Patent 5,837,732
ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-two patent family members in forty-five countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Japan Patent 2,009,502,889
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and thirty-nine patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Japan Patent 4,797,067
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and thirty-nine patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can VICTRELIS (boceprevir) generic drug versions launch?
Generic name: boceprevir
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 02, 2025
Generic Entry Controlled by: Japan Patent 2,008,542,383
VICTRELIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.
This drug has one hundred and ten patent family members in thirty-three countries.
The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.
When can VICTRELIS (boceprevir) generic drug versions launch?
Generic name: boceprevir
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 02, 2025
Generic Entry Controlled by: Japan Patent 2,012,250,996
VICTRELIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.
This drug has one hundred and ten patent family members in thirty-three countries.
The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.
When can VICTRELIS (boceprevir) generic drug versions launch?
Generic name: boceprevir
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 02, 2025
Generic Entry Controlled by: Japan Patent 5,160,415
VICTRELIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.
This drug has one hundred and ten patent family members in thirty-three countries.
The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.
When can XALKORI (crizotinib) generic drug versions launch?
Generic name: crizotinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 05, 2025
Generic Entry Controlled by: Japan Patent 2,007,153,893
XALKORI is a drug marketed by Pf Prism Cv. There are five patents protecting this drug.
This drug has one hundred and fifty-two patent family members in forty-eight countries.
See drug price trends for XALKORI.
The generic ingredient in XALKORI is crizotinib. One supplier is listed for this generic product. Additional details are available on the crizotinib profile page.
When can XALKORI (crizotinib) generic drug versions launch?
Generic name: crizotinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 05, 2025
Generic Entry Controlled by: Japan Patent 4,663,619
XALKORI is a drug marketed by Pf Prism Cv. There are five patents protecting this drug.
This drug has one hundred and fifty-two patent family members in forty-eight countries.
See drug price trends for XALKORI.
The generic ingredient in XALKORI is crizotinib. One supplier is listed for this generic product. Additional details are available on the crizotinib profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,008,540,523
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,009,531,449
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,011,068,653
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,012,211,190
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,012,236,843
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,013,136,642
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,015,098,497
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,015,117,244
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,016,183,200
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,017,031,223
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,017,031,224
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,018,100,292
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,019,218,352
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,021,035,970
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 4,644,737
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 5,138,753
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 5,150,780
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 5,350,217
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 5,934,670
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 6,013,535
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can BUNAVAIL (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch?
Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 13, 2025
Generic Entry Controlled by: Japan Patent 2,009,519,347
BUNAVAIL is a drug marketed by Bdsi. There are four patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.
This drug has eighty-three patent family members in twenty-six countries. There has been litigation on patents covering BUNAVAIL
See drug price trends for BUNAVAIL.
The generic ingredient in BUNAVAIL is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
When can BUNAVAIL (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch?
Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 13, 2025
Generic Entry Controlled by: Japan Patent 5,586,151
BUNAVAIL is a drug marketed by Bdsi. There are four patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.
This drug has eighty-three patent family members in twenty-six countries. There has been litigation on patents covering BUNAVAIL
See drug price trends for BUNAVAIL.
The generic ingredient in BUNAVAIL is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 16, 2025
Generic Entry Controlled by: Japan Patent 2,009,519,314
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 16, 2025
Generic Entry Controlled by: Japan Patent 2,013,049,715
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 16, 2025
Generic Entry Controlled by: Japan Patent 5,484,733
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 16, 2025
Generic Entry Controlled by: Japan Patent 5,709,826
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2025
Generic Entry Controlled by: Japan Patent 2,008,533,152
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has fifty patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2025
Generic Entry Controlled by: Japan Patent 2,013,091,643
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has fifty patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2025
Generic Entry Controlled by: Japan Patent 5,236,457
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has fifty patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2025
Generic Entry Controlled by: Japan Patent 5,671,514
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has fifty patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can SUSTOL (granisetron) generic drug versions launch?
Generic name: granisetron
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 28, 2024
Generic Entry Controlled by: Japan Patent 2,008,514,646
SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.
This drug has eighteen patent family members in ten countries.
See drug price trends for SUSTOL.
The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.
When can SUSTOL (granisetron) generic drug versions launch?
Generic name: granisetron
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 28, 2024
Generic Entry Controlled by: Japan Patent 2,012,107,064
SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.
This drug has eighteen patent family members in ten countries.
See drug price trends for SUSTOL.
The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.
When can SUSTOL (granisetron) generic drug versions launch?
Generic name: granisetron
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 28, 2024
Generic Entry Controlled by: Japan Patent 2,015,034,182
SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.
This drug has eighteen patent family members in ten countries.
See drug price trends for SUSTOL.
The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.
When can SUSTOL (granisetron) generic drug versions launch?
Generic name: granisetron
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 28, 2024
Generic Entry Controlled by: Japan Patent 2,017,008,113
SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.
This drug has eighteen patent family members in ten countries.
See drug price trends for SUSTOL.
The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.
When can SUSTOL (granisetron) generic drug versions launch?
Generic name: granisetron
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 28, 2024
Generic Entry Controlled by: Japan Patent 6,057,972
SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.
This drug has eighteen patent family members in ten countries.
See drug price trends for SUSTOL.
The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Japan Patent 2,008,535,781
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Japan Patent 2,009,526,751
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Japan Patent 2,010,248,265
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Japan Patent 2,013,018,778
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Japan Patent 2,014,132,031
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Japan Patent 2,015,117,243
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Japan Patent 2,016,020,374
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Japan Patent 2,016,199,561
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Japan Patent 2,017,105,826
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Japan Patent 5,038,912
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Japan Patent 6,046,876
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 16, 2025
Generic Entry Controlled by: Japan Patent 6,109,140
EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?
Generic name: indacaterol maleate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2024
Generic Entry Controlled by: Japan Patent 2,007,536,962
ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.
This drug has eighty-six patent family members in thirty-nine countries.
See drug price trends for ARCAPTA NEOHALER.
The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.
When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?
Generic name: indacaterol maleate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2024
Generic Entry Controlled by: Japan Patent 2,012,071,146
ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.
This drug has eighty-six patent family members in thirty-nine countries.
See drug price trends for ARCAPTA NEOHALER.
The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.
When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?
Generic name: indacaterol maleate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2024
Generic Entry Controlled by: Japan Patent 4,914,345
ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.
This drug has eighty-six patent family members in thirty-nine countries.
See drug price trends for ARCAPTA NEOHALER.
The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.
When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?
Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2024
Generic Entry Controlled by: Japan Patent 2,007,536,962
UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.
This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON
See drug price trends for UTIBRON.
The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.
When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?
Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2024
Generic Entry Controlled by: Japan Patent 2,012,071,146
UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.
This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON
See drug price trends for UTIBRON.
The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.
When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?
Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2024
Generic Entry Controlled by: Japan Patent 4,914,345
UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.
This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON
See drug price trends for UTIBRON.
The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Japan Patent 2,007,537,265
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Japan Patent 2,007,538,081
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Japan Patent 2,008,522,981
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Japan Patent 2,012,121,895
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Japan Patent 2,014,141,456
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Japan Patent 4,990,155
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 10, 2024
Generic Entry Controlled by: Japan Patent 5,108,509
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are eleven patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: belinostat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,008,540,499
BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ
See drug price trends for BELEODAQ.
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: belinostat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 2,012,188,444
BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ
See drug price trends for BELEODAQ.
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: belinostat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Japan Patent 5,108,750
BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ
See drug price trends for BELEODAQ.
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: